
Oxford-based biotech firm Adaptimmune has secured some significant financial support whilst also making changes to its board. David Mott (pictured), …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

